TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
ACIU

AC Immune Ltd

Healthcare · Biotechnology

2.70$ -0.6% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

AC Immune Ltd (ACIU) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 150 million CHF. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of CHF.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ACIU
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
161 156 145 131 125 132 120 113 209 197 313 296 315 299 288 273 257 239 228 211 203 261 236 217 206 186 169 156 143 183 167 238 244 231 211 190 172 154 137 150
160 155 142 129 123 130 116 109 205 193 307 290 309 293 282 267 251 232 220 203 195 203 177 158 148 128 112 99 86 125 110 181 188 172 152 132 114 97 80 93
158 152 138 124 117 124 110 103 199 156 222 206 212 194 183 177 177 161 151 104 94 82 58 63 45 32 57 40 32 78 57 52 32 36 20 26 28 27 19 28
158 152 138 124 117 124 110 103 199 186 302 286 302 289 278 262 247 226 216 199 189 198 174 154 141 123 105 93 80 103 105 175 158 165 146 127 108 92 75 75
1.3 1.4 2.0 2.6 3.6 3.7 4.2 2.6 3.4 4.1 1.8 0.5 0.9 1.4 0.7 1.0 1.3 1.6 0.7 0.7 0.1 1.0 0.2 0.4 0.1 0.4 0.2 0.7 0.3 15 0.3 0.4 25 1.1 0.9 0.5 0.4 1.0 0.2 14
0.0 0.0 -1.5 -1.5 -2.8 -0.9 -3.1 0.0 0.0 -0.4 0.0 0.0 0.0 -0.3 0.0 -0.6 0.0 0.0 0.0 0.0 -0.3 0.0 0.0 -0.3 – 0.0 -0.6 -0.3 -0.4 -0.6 -0.9 – – – – – – – – –
– 1.1 2.1 2.5 2.6 2.4 3.5 3.5 3.4 3.6 5.7 5.6 5.6 6.2 5.9 5.8 5.7 6.6 7.0 7.9 7.6 8.0 7.7 7.6 7.2 7.1 – 6.3 – – – – – – – – – – – –
– – – – – – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – 50 –
– – – – – – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – 233 – – – – 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 – 50
14 14 12 10 13 15 14 17 17 19 71 23 23 27 23 22 23 23 21 22 24 29 21 14 16 17 16 17 17 22 23 114 114 119 116 115 109 109 106 115
11 9.9 7.7 6.0 8.2 9.8 8.6 11 11 13 61 13 14 18 13 13 14 14 11 12 14 20 12 12 14 11 11 11 12 14 14 101 101 101 99 99 98 95 92 100
6.8 – – 0.4 0.4 0.4 0.5 0.0 0.0 0.3 48 0.7 0.8 1.1 0.8 0.8 0.8 0.4 0.4 0.6 0.6 0.6 0.6 0.6 0.6 0.5 0.6 0.6 0.6 0.7 0.7 0.7 0.7 1.0 1.0 1.0 1.0 0.9 0.8 0.8
2.8 4.0 2.6 1.0 1.4 1.1 1.2 2.0 0.5 2.0 0.8 0.2 0.0 0.1 0.8 1.4 1.0 2.2 0.4 0.3 0.2 2.0 0.5 0.3 1.5 0.9 1.1 1.4 1.5 1.7 2.8 1.4 1.4 2.7 2.4 2.7 1.6 2.1 1.3 1.5
– – – 0.4 0.4 0.4 0.5 0.6 0.6 0.2 0.2 0.3 0.3 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – –
146 142 133 121 113 117 106 95 192 178 242 273 292 272 266 251 233 215 207 189 179 232 214 203 190 169 153 139 126 161 145 123 130 112 95 75 62 45 32 35
-43 -47 -56 -68 -77 -73 -84 -94 -107 -122 -58 -74 -56 -76 -82 -97 -115 -133 -149 -167 -182 -201 -219 -230 -243 -264 -280 -296 -310 -316 -333 -355 -349 -368 -386 -407 -420 -440 -453 -450
50 57 57 57 57 57 57 57 65 71 71 71 72 72 72 72 72 72 74 74 74 79 79 79 84 84 84 84 84 84 99 100 101 101 100 101 99 101 99 99

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?